These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28968794)

  • 61. Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials.
    Plennevaux E; Moureau A; Arredondo-García JL; Villar L; Pitisuttithum P; Tran NH; Bonaparte M; Chansinghakul D; Coronel DL; L'Azou M; Ochiai RL; Toh ML; Noriega F; Bouckenooghe A
    Clin Infect Dis; 2018 Apr; 66(8):1164-1172. PubMed ID: 29300876
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response.
    Gilbert PB; Huang Y; Juraska M; Moodie Z; Fong Y; Luedtke A; Zhuang Y; Shao J; Carpp LN; Jackson N; Chambonneau L; Bouckenooghe A; Zambrano B; Frago C; Pallardy S; Noriega F
    Am J Trop Med Hyg; 2019 Jul; 101(1):164-179. PubMed ID: 31115304
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines.
    Sun W; Eckels KH; Putnak JR; Lyons AG; Thomas SJ; Vaughn DW; Gibbons RV; Fernandez S; Gunther VJ; Mammen MP; Statler JD; Innis BL
    J Infect Dis; 2013 Mar; 207(5):700-8. PubMed ID: 23225894
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical Efficacy, Safety, and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine (CYD-TDV) in Children: A Systematic Review with Meta-analysis.
    Malisheni M; Khaiboullina SF; Rizvanov AA; Takah N; Murewanhema G; Bates M
    Front Immunol; 2017; 8():863. PubMed ID: 28824613
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.
    Biswal S; Borja-Tabora C; Martinez Vargas L; Velásquez H; Theresa Alera M; Sierra V; Johana Rodriguez-Arenales E; Yu D; Wickramasinghe VP; Duarte Moreira E; Fernando AD; Gunasekera D; Kosalaraksa P; Espinoza F; López-Medina E; Bravo L; Tuboi S; Hutagalung Y; Garbes P; Escudero I; Rauscher M; Bizjajeva S; LeFevre I; Borkowski A; Saez-Llorens X; Wallace D;
    Lancet; 2020 May; 395(10234):1423-1433. PubMed ID: 32197105
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dengue vaccine: a valuable asset for the future.
    Jindal H; Bhatt B; Malik JS; S K S
    Hum Vaccin Immunother; 2014; 10(8):2245-6. PubMed ID: 25424928
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore.
    Harenberg A; Begue S; Mamessier A; Gimenez-Fourage S; Ching Seah C; Wei Liang A; Li Ng J; Yun Toh X; Archuleta S; Wilder-Smith A; Shek LP; Wartel-Tram A; Bouckenooghe A; Lang J; Crevat D; Caillet C; Guy B
    Hum Vaccin Immunother; 2013 Nov; 9(11):2317-25. PubMed ID: 23839107
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia.
    Lee JS; Lourenço J; Gupta S; Farlow A
    Vaccine; 2018 Apr; 36(17):2346-2355. PubMed ID: 29573874
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine.
    Wilder-Smith A; Massad E
    Expert Rev Vaccines; 2016; 15(4):437-41. PubMed ID: 26775653
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus.
    Dayan GH; Langevin E; Forrat R; Zambrano B; Noriega F; Frago C; Bouckenooghe A; Machabert T; Savarino S; DiazGranados CA
    Vaccine; 2020 Sep; 38(41):6472-6477. PubMed ID: 32773243
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of individual-level phase III data.
    Laydon DJ; Dorigatti I; Hinsley WR; Nedjati-Gilani G; Coudeville L; Ferguson NM
    Elife; 2021 Jul; 10():. PubMed ID: 34219653
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection.
    Guy B; Jackson N
    Nat Rev Microbiol; 2016 Jan; 14(1):45-54. PubMed ID: 26639777
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials.
    Harenberg A; de Montfort A; Jantet-Blaudez F; Bonaparte M; Boudet F; Saville M; Jackson N; Guy B
    PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004830. PubMed ID: 27459266
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children.
    Simasathien S; Thomas SJ; Watanaveeradej V; Nisalak A; Barberousse C; Innis BL; Sun W; Putnak JR; Eckels KH; Hutagalung Y; Gibbons RV; Zhang C; De La Barrera R; Jarman RG; Chawachalasai W; Mammen MP
    Am J Trop Med Hyg; 2008 Mar; 78(3):426-33. PubMed ID: 18337339
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine.
    Gromowski GD; Henein S; Kannadka CB; Barvir DA; Thomas SJ; de Silva AM; Jarman RG
    Vaccine; 2018 Apr; 36(18):2403-2410. PubMed ID: 29602701
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A recombinant live attenuated tetravalent vaccine for the prevention of dengue.
    Guy B; Noriega F; Ochiai RL; L'azou M; Delore V; Skipetrova A; Verdier F; Coudeville L; Savarino S; Jackson N
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28590795
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Four-year safety follow-up of the tetravalent dengue vaccine CYD-TDV.
    Wilder-Smith A
    Clin Microbiol Infect; 2018 Jul; 24(7):680-681. PubMed ID: 29581052
    [No Abstract]   [Full Text] [Related]  

  • 78. Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy.
    Rabaa MA; Girerd-Chambaz Y; Duong Thi Hue K; Vu Tuan T; Wills B; Bonaparte M; van der Vliet D; Langevin E; Cortes M; Zambrano B; Dunod C; Wartel-Tram A; Jackson N; Simmons CP
    Elife; 2017 Sep; 6():. PubMed ID: 28871961
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Safety, immunogenicity and efficacy of a recombinant tetravalent dengue vaccine: a meta-analysis of randomized trials.
    da Costa VG; Marques-Silva AC; Floriano VG; Moreli ML
    Vaccine; 2014 Sep; 32(39):4885-92. PubMed ID: 25045816
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans.
    Qiao M; Shaw D; Forrat R; Wartel-Tram A; Lang J
    Am J Trop Med Hyg; 2011 Oct; 85(4):724-31. PubMed ID: 21976579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.